Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
5
Neutral
1
Bullish
8
Bearish
37
Neutral
1
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Kerala Ayurveda Limited is a listed, full‑spectrum Ayurveda company operating product manufacturing, academies, resorts, clinics, hospitals, and health services across India, the USA and select international markets, offering over 400 products and multiple service brands including Ayurvedagram and Kerala Ayurveda Academy that span education, treatment and consumer goods.
In FY26 KAL delivered consolidated revenue of Rs.145.4 crores, a reported 19% year-on-year improvement (22% excluding discontinued lines) while the standalone entity crossed Rs.100 crores for the first time, driven by strong India E‑Product and Health Services growth, signaling meaningful recovery and scale in core operating segments.
Management projects an ambitious FY27 target of Rs.200 crores consolidated revenue (+38%), with operating revenue expected to grow 50% and the Global E‑Product segment flagged as the main growth engine targeting Rs.53 crores; this guidance is supported by specific e‑commerce, product and clinic expansion levers.
KAL expects to reach operating EBITDA break‑even by January 2027 despite a three‑fold increase in marketing investment, citing improved e‑commerce productivity, the Clinic Growth Model rollout, cost optimization measures and expected operating leverage from scale across product and health service verticals.
The company has a Vision 2030 plan to scale to Rs.1000 crores by 2030 and has allocated an investment envelope of Rs.200 crores over five years for talent, marketing, capex and working capital, while also completing a strategic consolidation by acquiring the remaining stake in its flagship resort, Ayurvedagram.
Pharmaceuticals & Biotechnology
Pharmaceuticals
179 Cr
High Risk
-6.8
34.8
—
7.5
448.00
130.00
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q2 FY19
Kerala Ayurveda Ltd (KERALAYUR) is currently trading at 131.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Kerala Ayurveda Limited is a listed, full‑spectrum Ayurveda company operating product manufacturing, academies, resorts, clinics, hospitals, and health services across India, the USA and select international markets, offering over 400 products and multiple service brands including Ayurvedagram and Kerala Ayurveda Academy that span education, treatment and consumer goods. In FY26 KAL delivered consolidated revenue of Rs.145.4 crores, a reported 19% year-on-year improvement (22% excluding discontinued lines) while the standalone entity crossed Rs.100 crores for the first time, driven by strong India E‑Product and Health Services growth, signaling meaningful recovery and scale in core operating segments. Management projects an ambitious FY27 target of Rs.200 crores consolidated revenue (+38%), with operating revenue expected to grow 50% and the Global E‑Product segment flagged as the main growth engine targeting Rs.53 crores; this guidance is supported by specific e‑commerce, product and clinic expansion levers. KAL expects to reach operating EBITDA break‑even by January 2027 despite a three‑fold increase in marketing investment, citing improved e‑commerce productivity, the Clinic Growth Model rollout, cost optimization measures and expected operating leverage from scale across product and health service verticals. The company has a Vision 2030 plan to scale to Rs.1000 crores by 2030 and has allocated an investment envelope of Rs.200 crores over five years for talent, marketing, capex and working capital, while also completing a strategic consolidation by acquiring the remaining stake in its flagship resort, Ayurvedagram.
Over the past 52 weeks, Kerala Ayurveda Ltd has traded between a low of ₹130.00 and a high of ₹448.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Kerala Ayurveda Ltd has a market capitalization of approximately 179.16. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Kerala Ayurveda Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -6.78 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 179.16 Cr, Kerala Ayurveda Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Kerala Ayurveda Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Kerala Ayurveda Ltd is -6.78. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The 34th AGM was held on September 28, 2026, and ran from 11:00 am to 12:35 pm via VC/OAVM.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
149.75 | 188 Cr | 15.71 | 2.55 | 0.00 | 45.24 | 27.08 | 16.22 | ||
152.80 | 188 Cr | 25.16 | 3.89 | 0.00 | 13.87 | 16.29 | 8.48 | ||
131.25 | 179 Cr | -6.78 | 7.50 | 0.00 | -148.86 | -9.23 | -19.10 | ||
494.10 | 176 Cr | 9.18 | 0.84 | 0.40 | 7.83 | 10.89 | 7.98 | ||
58.02 | 171 Cr | 12.94 | 1.39 | 0.00 | 20.04 | 19.30 | 8.92 | ||
46.07 | 170 Cr | -12.56 | 0.00 | 0.00 | 41.16 | -26.02 | -11.34 | ||
6.96 | 168 Cr | 524.94 | 4.79 | 0.00 | 0.90 | 1.13 | 0.84 | ||
| Median: 7 Co. | — | 131.25 | 176 Cr | 12.94 | 2.55 | 0.00 | 13.87 | 10.89 | 7.98 |
